Figure 2

Mean serum iduronate-2-sulfatase concentration-time profiles at week 23. Serum samples were taken from treated patients in each of the idursulfase-IT dosing groups following administration of idursulfase-IT (n values shown are per dose level), as well as following administration of intravenous (i.v.) idursulfase ~48 h later (n value is shown together, n = 9). These data are graphed together for comparative purposes. The level of iduronate-2-sulfatase protein in serum prior to idursulfase-IT administration (t = 0) was below the lower limit of quantification in 4/9 patients; the mean value shown at t = 0 reflects only those samples with quantifiable amounts (n = 2 for the 10-mg group; n = 1 for the 30-mg group; and n = 2 for the 1-mg group, respectively). Similarly, the level of iduronate-2-sulfatase in serum prior to i.v. idursulfase administration (t = 0) was below the lower limit of quantification in 7/9 patients; the mean value shown at t = 0 reflects only those samples with quantifiable amounts (n = 1 for the 10-mg group; n = 1 for the 30-mg group; and n = 0 for the 1-mg group, respectively). CSF, cerebrospinal fluid; IT, intrathecal; i.v., intravenous.